Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

Figure 2

Individual study and comparative meta-estimate hazard ratios and odds ratios for overall survival, progression-free survival, and response for bevacizumab with interferon (Bev + IFN), sunitinib (Sun), pazopanib (Pazo), and interferon alone (IFN) as first-line therapy for patients with clear cell renal cell carcinoma.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us